The manufacturers of ibrutinib are continually exploring new therapeutic applications for the drug. Ongoing research aims to extend its use to other cancers and autoimmune diseases. AbbVie and Janssen are also investing in next-generation BTK inhibitors to overcome resistance seen in some patients.
Future Prospects for Ibrutinib and its Manufacturers